58 results about "Musculoskeletal disease" patented technology

Methods of predicting bone or joint disease in a subject are presented. The method may include determining one or more micro-structural parameters, one or more macroanatomical parameters or biomechanical parameters of a joint in the subject. At least two of the parameters are combined to predict the risk of bone or articular disease. Additionally, methods of determining the effect of a candidate agent on any subject's risk of developing bone or joint disease are presented.

The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.

Disclosed herein is a gymnastic guide system displayed in a computer, and more particularly to such a gymnastic guide system in which program is executed to guide a gymnastic exercise every a fixed time interval in a computer so as to prevent musculoskeletal disease, etc., caused by a long-term computer work. The gymnastic guide system comprises: a hard disk for storing at least one video data related to gymnastic exercises therein; timer means for generating a certain signal therefrom every time when a predetermined time lapses; execution means for reading out the video data from the hard disk and executing the readout video data in response to the signal generated from the timer means; and a display section for displaying the execution process of the execution means in a moving picture fashion.

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

The present invention relates, in general, to biomarkers of musculoskeletal disease and, in particular, to methods of as diagnosing musculoskeletal disease, and/or predicting disease progression, by assaying for such biomarkers. The invention further relates to compounds and compositions suitable for use in such methods.

A method of treating a patient suffering from pain in the lower limb or a lower limb musculoskeletal disease is provided. The method includes placement of at least two calibrated, differential disturbances or protuberances under the patient's feet.

The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

The invention concerns pharmaceutical formulations comprising solvent/detergent (S/D)-treated plasma and a glycosaminoglycan such as hyaluronic acid, and their use for treating diseases, particularly musculoskeletal diseases.

The present invention provides a method for topical delivery of pharmacologically active chemicals into local tissues (skin, subcutaneous, muscle and joint tissues) via the administration of their specially designed cationic prodrugs with anode iontophoresis. The pharmacologically active chemicals are either negatively charged or neutral under the physiologic pH, which are not suitable to be delivered with the anode iontophoresis. The cationic prodrugs of such pharmacologically active chemicals are suitable for anode iontophoresis for improving delivery efficiency of these drugs into the local tissues. The cationic prodrugs can also be used in co-delivery with other cationic drugs such as vasoconstrictors or local anesthetic agents by iontophoresis for treatment of disorders in the local tissues. The anode iontophoresis delivery of the specially designed cationic prodrugs can provide higher drug concentrations in the local tissues, which can be used for better topical treatment of musculoskeletal diseases or skin diseases.

The present invention relates to a composition comprising an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides and one or more lipid moiety, wherein said one or more lipid moiety is covalently linked to said oligomeric compound either directly or via a spacer, and wherein preferably said oligomeric compound comprises from 5 to 40 monomer subunits, as well as pharmaceutical compositions thereof and their uses in the prevention or treatment of neuromuscular or musculoskeletal diseases such as Duchenne muscular dystrophy or Steinert disease.

The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated by culturing an eukaryotic cell derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart in a FBS-containing medium and a method for preparing the same. Adult stem cells according to the present invention are derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart. The adult stem cells have characteristics highly similar to human mesenchymal stem cells as well as remarkable cell growth at the initial step compared to human UCB-derived mesenchymal stem cells so that the cells are useful to treat canine incurable diseases and difficult-to-cure diseases. Furthermore, multipotent adult stem cells are effective to treat musculoskeletal diseases and neural diseases due to the ability to differentiate into osteogenic cells and neural cells.

The invention discloses a method, a compound and a composition for treating a musculoskeletal disease. A casing body is provided. A bevel edge cavity is arranged in the top end surface of the casing body, an entering groove is arranged in the inner bottom wall of the bevel edge cavity, first sliding connection cavities are symmetrically arranged in the inner walls of the left and right sides of the entering groove, a pushing block is slidably arranged in each first sliding connection cavity in a fitting mode, one side, away from the entering groove, of each first sliding connection cavity is communicated with a first transmission connection cavity, one side end surface, away from the entering groove, of the pushing block is fixedly provided with fixing blocks in longitudinal symmetry, a first link rod is fixedly arranged between one upper fixing block and one lower fixing block, adapter wheels are rotatably mounted on the outer surface of the first link rod in a circumferential direction and in a fitting mode, a first adapter shaft is rotatably mounted in the first transmission connection cavity in a fitting manner, the bottom extending tail end of the first adapter shaft is in power connection with a first electrical rotation machine, the outer surface of the first electrical rotation machine is fixedly arranged in the inner bottom wall of the first transmission connection cavity, deflecting wheels are fixedly arranged on the outer surface of the first adapter shaft in a circumferential direction, and the deflecting wheels abut against the adapter wheels.

A vegetable butter based dietary supplement of cetyl myristoleate is disclosed for use in the treatment of osteoarthritis and other joint inflammatory diseases of the musculoskeletal system in animals, especially equines. In its preferred form, the cetyl myristoleate is a vegetable butter-based and is administered in doses of about 4000 to about 4500 mg. The dosage may also include 3000 mg methylsulfonylmethane, 3000 mg glucosamine HCL and 1000 mg of Vitamin C.

An apparatus for determining a musculoskeletal disease may be disclosed. The apparatus may include a motion protocol learning unit configured to generate a first motion protocol used to determine a musculoskeletal disease in advance through learning, a motion protocol recognition model unit configured to generate a motion protocol recognition model for determining a musculoskeletal disease by using information of the first motion protocol, a body pose estimator configured to receive a user image to be recognized and estimate a body pose from the user image, and a disease classification and prediction unit configured to determine a musculoskeletal disease by matching the body pose and the motion protocol recognition model.

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

The invention is relevant to chemistry of organic compounds, pharmacology and medicine, and is related to prevention and treatment of musculoskeletal diseases in human and animals associated with the disorder of bone and/or cartilage metabolism, particularly with such musculoskeletal diseases as osteoporosis, osteoarthritis and osteochondrosis, using a new salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazine-2-yl)amino)-2H-pyrido[3,2-b][1,4]oxazine-3(4H)-one. A salt of this compound with 4-methylbenzenesulfonic acid